Adverum Biotechnologies Presents Updated Preclinical Data on ADVM-022 in Wet AMD at the 2017 Targeting Ocular Disorders Conference
Previously reported data using the industry standard, laser-induced choroidal neovascularization (CNV) model in a non-human primate study demonstrated that a single intravitreal administration of ADVM-022 had comparable efficacy in reducing grade IV CNV lesions to an intravitreal injection of standard-of-care anti-VEGF therapies. In addition, data showed durable anti-VEGF protein expression with therapeutic protein levels at least 20 weeks after a single intravitreal administration of ADVM-022.
Today, additional pharmacokinetic data are being presented, demonstrating sustained expression for 52 weeks, with only mild ocular inflammation following a single intravitreal administration of ADVM-022 in one non-human primate. In a separate study, sustained expression for at least seven months has been observed in several non-human primates. Adverum will continue to monitor these non-human primates to assess long-term durability of sustained expression of anti-VEGF protein after a single administration of ADVM-022.
“These additional long-term data continue to demonstrate sustained expression of anti-VEGF protein and that our novel vector enables intravitreal delivery,” said
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Adverum Contact:Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 cbutler@adverum.com
Source: Adverum Biotechnologies, Inc.